



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

1331-138

SERIAL NO.

08/460,186

APPLICANT

Reid W. Von Borstel, et al

FILING DATE

June 2, 1995

GROUP

1200

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A.K.	5,077,280	12/91	Sommadossi et al			
A.K.	4,874,602	10/89	Calabresi et al			
A.K.	4,950,466	8/90	Calabresi et al			
A.K.	4,757,139	7/88	Kawaguchi et al			

FOREIGN PATENT DOCUMENTS

							TRANSLATION	
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
A.K.	WO 91/16315	10/91	PCT	_____	_____			
	WO 89/09603	10/89	PCT	_____	_____			
	WO 90/09163	8/90	PCT	_____	_____			
	WO 90/08550	8/90	PCT	_____	_____			
	0 056 265	7/82	European Patent Appln.	_____	_____			
	1 473 148	5/77	United Kingdom	_____	_____			
	1 297 398	11/72	Great Britain	_____	_____			
	60-174797	2/84	Japan (Abstract)	_____	_____			
	WO 89/03837	5/89	PCT	_____	_____			
	WO 89/03838	5/89	PCT	_____	_____			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

A.K.	-	D.S. Martin et al, "Cancer Res., 42, 3964-3970, 1982, "High-Dose 5-Fluorouracil with Delayed Uridine 'Rescue' in Mice."
	-	D.S. Martin et al., "Cancer Res., 43, 4653, 1983, "Improved Therapeutic Index with Sequential N-Phosphonacetyl-L-aspartate plus High-Dose Methotrexate plus High-Dose 5-Fluorouracil and Appropriate Rescue."
	-	Proceedings of AACR, 28, 195, March 1987 - No. 775 - "Phase I Clinical and Pharmacokinetics Study of Orally Administered Uridine."
	-	C.J. van Groenigen et al, Cancer Treatment Reports, Vol. 70, No. 6, 745, June 1986, "Clinical and Pharmacokinetic Studies of Prolonged Administration of High-Dose Uridine Intended for Rescue from 5-FU Toxicity."
	-	N.I. Belyanchikova et al, Byulleten 'Eksperimental' noi Biologii i Meditsiny, Vol. 91, No. 1, p67-69, "Particular Features of Hematopoiesis in Mice Protected by Deoxycytidine Against the Lethal Effect of Cytosar."
	-	K. Bhalla et al, Blood, Vol. 70, No. 2, August 1987, pp 568-571, "Deoxycytidine Preferentially Protects Normal Versus Leukemic Myeloid Progenitor Cells from Cytosine Arabinoside-Mediated Cytotoxicity."
	-	S. Grant et al, Leukemia Research, M.S. 045, Pergamon Journals Ltd., "Interaction of Deoxycytidine and Deoxycytidine Analogs in Normal and Leukemic Human Myeloid Progenitor Cells."
	-	K. Bhalla et al, Leukemia, Vol. 2 (10) 709-10, 1988, "Phase I Clinical and Pharmacologic Study of Deoxycytidine."

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET NO.

1331-138

SERIAL NO.

08/460,186

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Reid W. Von Borstel, et al

FILING DATE

June 2, 1995

GROUP

~~1803~~ 1200

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

				TRANSLATION			
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

o	AJK	-	J. Sommadossi et al, <u>Timicrobial Agents and Chemotherapy</u> , Vol. 32, No. 7, p. 997-1001, July 1988, "Uridine Reverses the Toxicity of 3'-Azido-3'-Deoxythymidine in Normal Human Granulocyte-Macrophage Progenitor Cells In Vitro without Impairment of Antiretroviral Activity."
		-	A. Falcone et al, <u>Blood</u> , Vol. 76, No. 11, pp 2216-2221, (December 1, 1990), "Differential Effect of Benzylacyclouridine on the Toxic and Therapeutic Effects of Azidothymidine in Mice."
		-	K. Bhalla et al, <u>Blood</u> , Vol. 74, No. 6, pp 1923-1928 (November 1, 1989), "2'-Deoxycytidine Protects Normal Human Bone Marrow Progenitor Cells In Vitro Against the Cytotoxicity of 3'-Azido-3'-Deoxythymidine with Preservation of Antiretroviral Activity."
		-	Z. M. Gomez et al, <u>Antimicrobial Agents and Chemotherapy</u> , Vol. 34, No. 7, p. 1371-1375, July 1990, "Antimalarial Activity of a Combination of 5-Fluoroorotate and Uridine in Mice."
		-	Oligonucleotide Products, Sigma Catalog, pp. 1736-1738
		-	M. Iigo et al, <u>Biochemical Pharmacology</u> , Vol. 39, No. 7, 1247 (1990), "Differential Effects of 2,2'-Anhydro-5-Ethyluridine, A Uridine Phosphorylase Inhibitor, on the Antitumor Activity of 5-Fluorouridine and 5-Fluoro-2'-Deoxyuridine."
o		-	P. Calabresi et al, <u>Blood</u> , Vol. 76, No. 11, pp 2210-2215 (December 1990), "Benzylacyclouridine Reverses Azidothymidine-Induced Marrow Suppression Without Impairment of Anti-Human Immunodeficiency Virus Activity."
		-	W.D. Ensminger et al, <u>Biochemical Pharmacology</u> , Vol. 28, p. 1541-1545 (1979), "Thymidine 5'-O-Pivaloate, A Prodrug Derivative of Thymidine with Potential Applications in High-Dose Methotrexate Therapy."
		-	Martin et al, <u>Journal of Pharmaceutical Sciences</u> , Vol. 76, No. 2, pp 180-183, issued February 1987, "Synthesis and Antiviral Activity of Various Esters of 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine."
		-	Casida et al, <u>Biochemical Pharmacology</u> , Vol. 15, pp 627-644, Issued 1966, "3',5'-Diester of 5-Fluoro-2'-Deoxyuridine and Thymidine Hydrolysis by Esterases in Human, Mouse, and Insect Tissue."
		-	Losse et al, <u>Chemical Abstracts</u> , Vol. 118, Issued 1993, "A convenient pathway to 2'-(tert-butyloxycarbonyl)-ribonucleosides," p. 884, col. 1, abstr. no. 60026c, J. Prakt. Chem./Chem.-Ztg., 334(6), 531-532

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-FB-A820 (also PTO-1449)